Eμ-myc, Eμ-myc/CrmA, Eμ-myc/bcl-2, Eμ-myc/p53−/−, and Eμ-myc/apaf-1−/− lymphomas, different from those used in data presented in Figures 1 through 5, were injected into C57BL/6 mice, and the therapeutic efficacy of LAQ824 and LBH589 was assessed in tumor-bearing mice
| Eμ-myc lymphoma . | Median survival, d (P) . | WBC, ×109/mL, mean ± SE . |
|---|---|---|
| Eμ-myc#2 | ||
| Vehicle | 22 | 38.7 ± 1.3 |
| LAQ824 | 28 (.003) | 9.9 ± 1.5 |
| LBH589 | 31.5 (< .001) | 3.4 ± 0.3 |
| Eμ-myc/CrmA#2 | ||
| Vehicle | 18 | 19.4 ± 0.8 |
| LAQ824 | 22 (< .001) | 10.8 ± 2.7 |
| LBH589 | 26.5 (< .001) | 11.0 ± 1.8 |
| Eμ-myc/bcl-2#2 | ||
| Vehicle | 21 | 52.6 ± 11.2 |
| LAQ824 | 19 | 41.0 ± 7.4 |
| LBH589 | 19 | 23.4 ± 7.5 |
| Eμ-myc/p53−/−#2 | ||
| Vehicle | 20.5 | 19.6 ± 1.5 |
| LAQ824 | 23.5 (.002) | 12.5 ± 3.2 |
| LBH589 | 36.5 (< .001) | 6.0 ± 0.8 |
| Eμ-myc/apaf-1−/−#2 | ||
| Vehicle | 29 | 48.1 ± 4.1 |
| LAQ824 | 44 (.002) | 16.4 ± 2.6 |
| LBH589 | 47.5 (.004) | 2.5 ± 0.3 |
| Eμ-myc lymphoma . | Median survival, d (P) . | WBC, ×109/mL, mean ± SE . |
|---|---|---|
| Eμ-myc#2 | ||
| Vehicle | 22 | 38.7 ± 1.3 |
| LAQ824 | 28 (.003) | 9.9 ± 1.5 |
| LBH589 | 31.5 (< .001) | 3.4 ± 0.3 |
| Eμ-myc/CrmA#2 | ||
| Vehicle | 18 | 19.4 ± 0.8 |
| LAQ824 | 22 (< .001) | 10.8 ± 2.7 |
| LBH589 | 26.5 (< .001) | 11.0 ± 1.8 |
| Eμ-myc/bcl-2#2 | ||
| Vehicle | 21 | 52.6 ± 11.2 |
| LAQ824 | 19 | 41.0 ± 7.4 |
| LBH589 | 19 | 23.4 ± 7.5 |
| Eμ-myc/p53−/−#2 | ||
| Vehicle | 20.5 | 19.6 ± 1.5 |
| LAQ824 | 23.5 (.002) | 12.5 ± 3.2 |
| LBH589 | 36.5 (< .001) | 6.0 ± 0.8 |
| Eμ-myc/apaf-1−/−#2 | ||
| Vehicle | 29 | 48.1 ± 4.1 |
| LAQ824 | 44 (.002) | 16.4 ± 2.6 |
| LBH589 | 47.5 (.004) | 2.5 ± 0.3 |
Data represent the median survival times derived from Kaplan-Meier curves and white blood cell (WBC) counts taken 3 days after treatment with vehicle, LAQ824, or LBH589 (3 mice per data point).